ERCC1 and ovarian cancer: We have recently demonstrated that human ovarian cancer cell lines as well as primary- and ascites-derived ovarian cancer cells treated with cisplatin or paclitaxel generate a surviving residual population of cells which display enhanced expression of the chemoresistant-associated markers ERCC1 and β-tubulin as well as enhanced expression of CSC-like markers CD44, CD24, CD133, CD117, and EpCAM, compared to parental untreated ovarian cancer cells (6, 9, 29).